Chris focuses his practice on biotechnology patent preparation and prosecution across RNA interference (RNAi), antibody, microbiology, virology, cell biology, and genomic technologies. He also provides strategic IP counsel to academic and biotech industry clients on domestic and international IP portfolio management.
He is experienced in the preparation and prosecution of US and foreign patent applications related to biotechnology and biochemistry, including patents in the fields of oligonucleotide therapeutics, cell biology, genomics, immunology, microbiology, and virology. As well, Chris's experience includes IP due diligence and the preparation of noninfringement, invalidity, and freedom-to-operate opinions.
Prior to joining Mintz Levin, Chris was a patent attorney in the intellectual property practice of another international law firm. Prior to this, he was director of intellectual property at Dicerna Pharmaceuticals, Inc., where he was responsible for managing, prosecuting, and growing the company's portfolio of RNAi-relevant patent applications through multiple stages of venture funding, partnering, collaborations, licensing, and due diligence, including procurement of broad claims of high value that protect the company's core drug platform. Before Dicerna, he was an attorney/patent agent and a technology specialist in the Boston offices of two other law firms.
Before entering the legal profession, Chris performed his postdoctoral research at MIT's Whitehead Institute, where he was a Damon Runyon Cancer Research fellow in the laboratory of Dr. Eric Lander. Chris did his doctoral research at University of California - San Diego, as a Markey fellow in the laboratory of Dr. Scott Emr.
• Directed an RNAi-relevant patent portfolio, including the prosecution of pending applications to issuance of broad claims of high value.
• Prosecuted an international portfolio of applications for an immunological therapeutic agent now in clinical trials.